Wikipedia

mRNA-1283

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.[2][3]

mRNA-1283
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA
Clinical data
Trade namesSpikevax[1]
Routes of
administration		Intramuscular

Compared to prior mRNA vaccines, this candidate has a storage temperature of 2-5 °C, compatible with vaccine storage in a standard refrigerator, rather than low temperature freezers.[4] Additionally, the vaccine will be packaged in prefilled syringes, reducing burden on healthcare workers and potentially increasing access.[5]

Clinical Trial

edit

In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.[6] As of May 2024, the vaccine candidate is in Phase 3 clinical trials, with an estimated completion date of late August 2024.[7] Preliminary results from this trial indicated the vaccine produced a strong immune response, especially in patients over 65, who are at greater risk for severe outcomes from COVID-19.[8]

References

edit
  1. ^ "Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day". Bloomberg. 9 September 2021. Retrieved 29 April 2022.
  2. ^ "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.
  3. ^ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.gov. 30 November 2021. NCT05137236. Retrieved 30 November 2021.
  4. ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.
  5. ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.
  6. ^ Yassini P, Hutchens M, Paila YD, Schoch L, Aunins A, Siangphoe U, Paris R (December 2023). "Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults". Human Vaccines & Immunotherapeutics. 19 (1): 2190690. doi:10.1080/21645515.2023.2190690. PMC 10128428. PMID 37074202.
  7. ^ "A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)". ClinicalTrials.org. Retrieved 30 May 2024.
  8. ^ "Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine". news.modernatx.com. Retrieved 30 May 2024.
 
Scholia has a profile for mRNA-1283 (Q110263526).


 

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

 

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=MRNA-1283&oldid=1226467700"